BDNF and schizophrenia: The text suggests that cannabis exposure may contribute to the development of schizophrenia or psychotic disorders, but it is not sufficient to cause these conditions alone. The study found no significant differences between the groups treated with CBD and placebo in respect to BDNF levels at baseline and after 6 weeks, and no significant side effects were recorded